nivolumab,ipilimumab
bms
['nivo', 'check,mate,914', 'sarcoma']
sub group analyses from checkmate 914 (part a): overall no os benefit in itt population. selected patients based on pdl1, sarcomatoid feature may get benefits from adjuvant nivo-ipi buy study may not powered for those endpoints. #asco23 
On the road! Medical Oncologist & Prof @AnkaraUni | GU cancer expert  🔬| Diversity & Equity 📢 Advocate 💫  🌍 #Oncology #GenitourinaryCancer